Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Amplia Therapeutics Ltd
ATXCurrent price
0.091 AUD
-0.0089 AUD (-9.00%)
Last closed
0.096 AUD
Company
www.ampliatx.com
ISIN
AU0000023822
Sector
Healthcare
Industry
Biotechnology
Exchange
Australian Securities Exchange
Capitalization
30 647 826 AUD
Yield for 12 month
+19.41 %
1Y
3Y
5Y
10Y
15Y
ATX
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia. Address: 350 Queen Street, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.1 AUDP/E ratio
–Dividend Yield
–Current Year
+4 424 831 AUD
Last Year
+1 182 030 AUD
Current Quarter
+1 991 780 AUD
Last Quarter
+2 433 050 AUD
Current Year
+3 985 612 AUD
Last Year
+1 109 122 AUD
Current Quarter
+1 663 278 AUD
Last Quarter
+2 390 370 AUD
Key Figures ATX
1 year
3 years
5 years
10 years
EBITDA
-4 531 017 AUD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-17.04 %
PEG Ratio
–
Return On Equity TTM
-33.05 %
Wall Street Target Price
1.1 AUD
Revenue TTM
4 424 832 AUD
Book Value
0.059 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
38.4 %
Dividend Yield
–
Gross Profit TTM
973 053 AUD
Earnings per share
-0.02 AUD
Diluted Eps TTM
-0.02 AUD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-101.14 %
Dividend Analytics ATX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
30.04.2018
Dividend Date
–
Stock Valuation ATX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
7.2412
Enterprise Value EBITDA
-1.6534
Price Book MRQ
2.8238
Financials ATX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATX
For 52 weeks
0.055 AUD
0.18 AUD
50 Day MA
0.13 AUD
Shares Short Prior Month
–
200 Day MA
0.09 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart